AB474 / Arcus Biosci - LARVOL DELTA

Development of [99mTc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. (PubMed, J Med Chem) - "From this series, [99mTc]TcO-5 ([99mTc]TcO-ABX474, Kd(PSMA) = 6.1 ± 1.7 nM) displayed the most advantageous properties for SPECT imaging of PCa: high and fast tumor uptake accompanied by rapid clearance from nontarget tissues, leading to faster pharmacokinetics than observed for the reference [99mTc]Tc-PSMA-I&S. Furthermore, [99mTc]TcO-5 performed similar to the established PSMA-PET radioligand [68Ga]Ga-PSMA-11."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

First Experiences with the new 99mTc labelled PSMA ligand [99mTc]TcO-ABX474 in Patients with Advanced Prostate Cancer Prior to PSMA targeted Radioligand Therapy (SNMMI 2024) - "This study represents the first clinical experiences with [99mTc]TcO-ABX474 imaging in patients with advanced prostate cancer prior to PSMA targeted radioligand therapy. This non-invasive and cost-effective imaging modality showed comparable results to imaging with PET-CT and post-therapeutic SPECT/CT. It may therefore be suitable for use in the decision-making process for radioligand therapy with 177Lu-PSMA."

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Salivary Gland Cancer • Solid Tumor • FOLH1

Dose Changes for Long-term Opioid Patients Following a State Opioid Prescribing Policy. (PubMed, Med Care) - "Slower dose escalations, rather than faster dose de-escalation, likely explain post-law reductions in doses over 50 MME. Slower dose de-escalations may be due to longer days supply post-policy."

Journal • Pain

Targeting immune-suppressive myeloid cell pathways for the treatment of cancer (SITC 2019) - " Recombinant and endogenous ARG1 from human granulocytic lysates were used to determine AB474 potency... Myeloid cells are associated with blunted responses to checkpoint protein blockade. High expression of both PI3Kg and ARG1 within suppressive immune subsets contributes to the dampening of pro-inflammatory responses. Inhibiting these targets can reduce immunosuppression, enhance anti-tumor responses and act in concert with immune checkpoint blockade and other immunotherapies."

IO Biomarker • PD(L)-1 Biomarker